Neflamapimod endorsement based on targeted mechanism of action, demonstrated clinical activity in neurodegenerative diseases, and encouraging ...

An inflammatory sugar molecule produced by certain gut bacteria may play a key role in driving ALS, a study found.

CAMBRIDGE, Mass., July 1, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NRSN) (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe ...

Using machine learning models, researchers at Michigan Medicine have identified a potential way to diagnose amyotrophic lateral sclerosis, or ALS, earlier from a blood sample, a study suggests.

ARLINGTON, Va., Feb. 3, 2026 /PRNewswire/ -- The ALS Association today applauded the reintroduction of the ALS Better Care Act bipartisan legislation to expand access to high-quality multidisciplinary ...

VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the first participant has been dosed in its Phase 1/2 PIONEER-ALS trial evaluating ...

ST. PETERSBURG, Fla. — The disease ALS is often described as a thief — stealing a person’s ability to move, speak and eventually breathe, while their mind stays fully aware. It’s also one of the most ...

Rickey Malloy (left), who receives tofersen treatment for SOD1-ALS at WashU Medicine, plays a round of golf with his wife, Jenny, and their son, Kash. Long-term use of tofersen, a new drug approved by ...